Saxagliptin given in combination with metformin as initial therapy improves glycaemic control in patients with type 2 diabetes compared with either monotherapy: a randomized controlled trial

2009294 citationsJournal Articlebronze Open Access

Authors

Mauricio Jadzinsky · El Hospital General de Agudos Carlos G. Durand

Andreas Pfützner · Institut für Klinische Forschung und Entwicklung

Elizabeth Paz-Pacheco · University of Asia and the Pacific

Zherong Xu · Bristol-Myers Squibb (United States)

Elsie Allen · Bristol-Myers Squibb (Germany)

R. Chen · Bristol-Myers Squibb (Germany)

CV181‐039 Investigators

Abstract

Saxagliptin + metformin as initial therapy led to statistically significant improvements compared with either treatment alone across key glycaemic parameters with a tolerability profile similar to the monotherapy components.

Topics & Keywords

Diabetes Treatment and Management Metabolism, Diabetes, and Cancer Diabetes Management and Research

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: Diabetes Obesity and Metabolism

Volume 11, Issue 6, pp. 611-622

DOI: 10.1111/j.1463-1326.2009.01056.x

Field-Weighted Citation Impact: 28.34